Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy Participants

NCT05766709 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05766709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05766709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy Participants
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
March 2, 2023
Completion date
February 9, 2024
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis